sulfanilamide
Trade name: avc
Small moleculeapproved
Approved
Jun 5, 1965
Sulfanilamide is an anibiotic drug, which has been used for decades for the treatment of vulvovaginal candidiasis. The drug blocks folic acid synthesis in bacterias by inhibitin the enzyme dihydropteroate synthase. — NCATS
Clinical trial activity
1 trials · 1 clinical orgs · 5 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2015 (NCT02603575)
Timeline
1960s
- Jun 5, 1965
Mylan — Earliest FDA Approval
- Jun 5, 1965
Mylan — NDA Secondary Org
- Jun 5, 1965
Mylan — NDA Organization
- Jun 5, 1965
PHARMOBEDIENT — Marketing Organization
1980s
- Sep 19, 1985
Cosette — Marketing Organization
- Sep 19, 1985
G & W Laboratories Inc. — Marketing Organization
- Sep 19, 1985
ACP Nimble — Marketing Organization
Indications
Approved for
Mechanism of action
- Bacterial dihydropteroate synthaseINHIBITOR
folP inhibitor
Broad spectrum
Approval history
- approvedJun 5, 1965
Chemistry & pharmacology
Loading structure…
SMILES
NC1=CC=C(C=C1)S(N)(=O)=O- Mol. weight
- 172.205 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Topical
- Availability
- Discontinued
Oral
No
Parenteral
No
Topical
Yes
Sources
- WikipediaSulfanilamide ↗
- NCATS21240MF57M ↗
- ChEMBLCHEMBL21 ↗
Also known as
- 4-aminobenzene-1-sulfonamide
- 4-aminobenzenesulfonamide
- 4-aminobenzenesulfonamide
- 4-aminobenzene sulfonic acid amide
- 4-aminobenzene sulfonic acid amide
- 4-azanylbenzenesulfonamide
- 4-azanylbenzenesulfonamide
- avc
- avc
- azol polvo
- p-aminobenzenesulfamide
- p-aminobenzenesulfamide
- p-aminobenzenesulfonamide
- p-aminobenzenesulfonamide
- para-aminobenzenesulfonamide
- para-aminobenzenesulfonamide
- parazol
- prontosil album
- prontosil album
- prontosil flavum
- prontosil red
- prontosil rubrum
- red streptocide
- sa
- sa
- streptocide
- streptocide
- streptocide
- streptozon
- sulfamidochrysoidin
- sulfamidochrysoidine
- sulfamidyl
- sulfamine
- sulfamine
- sulfamine
- sulfana
- sulfanalone
- sulfanidyl
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide
- sulfanilamide barium salt
- sulfanilamide cadmium salt
- sulfanilamide hydrochloride
- sulfanilamide lithium salt
- sulfanilamide magnesium salt
- sulfanilamide monohydrate
- sulfanilamide silver salt
- sulfanilamide sodium salt
- sulfanilamide strontium salt
- sulfanilamide zinc salt
- sulfonamidochrysoidine
- sulfonylamide
- sulphanilamide
- sulphanilamide
- sulphanilamide
- sulphonamide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02603575 | N/A | Nov 1, 2015 | Capital Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 1 | 1 | 2015 |
1 organizations
Page 1 / 1
Marketing (6)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ACP Nimble | For profit | MKTG | Sep 19, 1985 |
| Cosette | For profit | MKTG | Sep 19, 1985 |
| G & W Laboratories Inc. | For profit | MKTG | Sep 19, 1985 |
| Mylan | For profit | NDA2 | Jun 5, 1965 |
| Mylan | For profit | NDA | Jun 5, 1965 |
| PHARMOBEDIENT | For profit | MKTG | Jun 5, 1965 |